Addus HomeCare Corporation (ADUS) 주식 분석

회사 개요

Addus HomeCare Corporation is a leading provider of personal care services catering to the elderly, chronically ill, disabled individuals, and those at risk of hospitalization or institutionalization within the United States. The company operates within the Healthcare sector, specifically in the Medical Care Facilities industry, which reflects its focus on delivering essential support services to vulnerable populations rather than manufacturing medical equipment or drugs. As a mid-to-large-cap entity, the company possesses a market capitalization of $1.73B and generates annual revenue of $1.42B, supported by a workforce of 5,982 employees. These financial metrics indicate that Addus has established a significant operational footprint, commanding a substantial market valuation that suggests strong investor confidence in its recurring revenue model derived from long-term care contracts.

재무 건전성

The company reported a trailing twelve-month revenue of $1.42B with a net income of $95.91M and an EBITDA of $156.23M, highlighting a substantial gap between gross revenue and bottom-line profit that underscores the capital-intensive nature of its service delivery and operational cost structure. Operating a free cash flow of $72.16M demonstrates that the business generates sufficient cash to cover its operational expenses and capital expenditures, providing the financial flexibility necessary to fund organic growth initiatives without immediate reliance on external financing. Profitability is assessed across three key margins, where the gross margin stands at 32.5%, the operating margin is 11.3%, and the profit margin reaches 6.7%, indicating that for every dollar of revenue, the company retains a significant portion after direct costs but faces substantial operating expenses typical of the labor-intensive home care sector. The balance sheet shows a total cash balance of $81.62M against total debt of $171.36M, resulting in a debt-to-equity ratio of 15.79%, which suggests a leveraged position where debt obligations exceed equity capitalization, a common structure for growth-oriented service firms. Liquidity is robust, evidenced by a current ratio of 1.80, meaning the company holds assets sufficient to cover short-term liabilities nearly twice over, ensuring it can meet its immediate financial obligations comfortably. Return on Equity stands at 9.3% while Return on Assets is 6.1%, revealing that management is effectively utilizing shareholder equity to generate returns, though the lower ROA relative to ROE points to the impact of the company's current debt level on overall asset efficiency.

밸류에이션 평가

Valuation multiples show a trailing P/E ratio of 17.77 and a forward P/E of 12.46, implying that the market expects earnings growth that will compress the multiple over time as the stock price adjusts to anticipated higher profit levels. The price-to-book ratio is recorded at 1.55, indicating that the market values the company at 55% above its tangible book value, which can reflect intangible assets such as brand reputation, proprietary care models, or expected future cash flows that are not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.22 and an EV/EBITDA of 11.35, suggesting that investors are willing to pay a moderate premium relative to sales while valuing operating earnings at a level consistent with other mature healthcare service providers. Price action over the last year has seen the stock trade between a 52-week high of $124.44 and a low of $90.89, placing the current trading price within a range that reflects recent market volatility and investor sentiment shifts. The beta of 0.96 indicates that the stock's price volatility is slightly less than the broader market, suggesting a relatively stable correlation with general market movements that may appeal to investors seeking defensive exposure within the healthcare sector.

Growth & Income

Growth dynamics are characterized by a revenue growth rate of 25.6% year-over-year and an earnings growth rate of 52.1% year-over-year, demonstrating that profitability is expanding at a significantly faster pace than top-line sales, which often signals improving operational leverage or cost efficiencies. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that retained earnings are fully reinvested into business expansion, technology upgrades, and talent acquisition rather than distributed to shareholders. This reinvestment strategy prioritizes compounding growth through market share acquisition and service quality improvements over providing immediate income to investors. The overall profile presents a high-growth trajectory driven by demographic tailwinds in the aging population, where accelerating earnings growth outpaces revenue expansion to deliver superior returns to equity holders.